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The antimicrobial and hemolytic activities of a host defense peptide can be controlled by its modification as
a propeptide of reduced net charge, which can then be processed by neutrophil elastase, a serine protease
involved in chronic airway inflammation and infections associated with cystic fibrosis.
Host defense peptides (HDPs) are multifunctional molecu-
lar effectors of innate immunity in multicellular organisms (3,
8, 26). Deficiencies in their activity or expression levels can be
associated with enhanced susceptibility to infections (6) and to
chronic infections in conditions such as cystic fibrosis (CF)
(19). While there is a sound underlying principle in compen-
sating disease-associated deficiencies in HDPs with exogenous
peptides, their potential toxicities contend with their localized
administration to sites of infection (10, 26). The activities of
endogenous HDPs themselves can be stringently controlled
(24). HDPs expressed as inactive prepropeptides are activated
by proteolytic cleavage of an anionic profragment masking the
net positive charge of the C-terminal mature sequence (9).
Human cathelicidin hCAP18/LL-37, for example, is activated
by proteinase 3, while other neutrophilic serine proteases, such
as neutrophil elastase (NE), can also cleave the profragment in
vitro (1, 25). As this enzyme is associated with chronic airway
inflammation and infections in CF patients (13), a prodrug
approach analogous to the natural control mechanism exerted
on HDPs and that exploits the abnormal concentrations of NE
in the CF lung is reported here.
Synthetic propeptides were prepared by modification of an
HDP with an anionic profragment, using L-P18, an -helical,
salt-resistant, cecropin A-magainin 2 hybrid sequence, identi-
fied by K.-S. Hahm’s group (20, 21). Peptides were assembled
by solid-phase synthesis (14), purified by reversed-phase high-
performance liquid chromatography, and characterized by ma-
trix-assisted laser desorption ionization–time of flight mass
spectrometry. Six propeptides were synthesized by elongating
the parent sequence (KWKLFKKIPKFLHLAKKF-NH2) at its
N terminus with a trialanine linker as an NE substrate (2) and
from 2 to 7 glutamic acids to mask the net charge determinant
(8) of the mature peptide’s antimicrobial activity. When
more than 4 glutamic acids were added, a -alanine spacer was
introduced between the fourth and fifth glutamates, to reduce
interchain association effects (11).
The antimicrobial activities of these peptides were assessed
for two representative CF pathogens, Staphylococcus aureus
(SH1000) and Pseudomonas aeruginosa (PAO1). MICs (Table
1) were determined by the broth microdilution method, as
recommended by the Clinical and Laboratory Standards Insti-
tute. Typical MICs of L-P18 for P. aeruginosa and S. aureus
were 32 M and 64 M, respectively, while MICs of all pro-
peptides were higher than 128 M. As the activities of -he-
lical membrane-active peptides have been suggested to be in-
dependent of the stereochemistry of their constitutive amino
acids (23), the enantiomeric D-P18 was subsequently used to
prevent their proteolytic degradation by bacterial proteases
(15) and NE itself. Assembly from L-amino acids was main-
tained for the trialanine and polyglutamate sequences. D-P18
had lower MICs than its enantiomeric counterpart, with values
of 8 and 16 M for P. aeruginosa and S. aureus, respectively. A
propeptide with a MIC of 128 M against both organisms was
generated by extending this D-P18 with a trialanine linker and
an N-terminally acetylated tetraglutamate motif (Ac-E-E-E-E-
A-A-A-k-w-k-l-f-k-k-i-p-k-f-l-h-l-a-k-k-f-NH2, abbreviated Ac-
E4-A3–D-P18 here) (Fig. 1). Reducing the overall charge of the
mature sequence from 8 to 3 resulted in activity differen-
tials of 8 and 16 against S. aureus and P. aeruginosa, respec-
tively.
Reactivation studies of Ac-E4-A3–D-P18 were conducted by
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susceptibility testing in the presence of purified human NE at
concentrations of 0.075 and 0.15 g/ml. These concentrations,
while significantly lower than physiological concentrations in
sputum or bronchoalveolar lavage fluid (26 to 100 g/ml) of
CF patients (7, 17), were sufficient to reactivate partly or fully
the propeptide. Its MICs against S. aureus were 32 and 16 M
at enzyme concentrations of 0.075 and 0.15 g/ml, respectively.
Propeptide reactivation was also observed against P. aerugi-
nosa, with a MIC of 16 M at an enzyme concentration of 0.15
g/ml, although NE can have direct antibacterial activity
against Gram-negative organisms (16). For S. aureus, control
tests performed with NE alone or with D-P18 showed that NE
had neither antimicrobial activity alone nor additive activity in
the presence of D-P18. Also, the activity of D-P18 remained
unaffected by the equimolar addition of the profragment linker
(Ac-E-E-E-E-A-A-A-OH; synthesized separately), indicating
that this promoiety (18) does not hinder the released sequence
by electrostatic interactions. The results reported in Table 1
indicate that the reactivation of Ac-E4-A3–D-P18 can be per-
formed in a concentration-dependent manner with NE and
could be exploited to confine the activity of D-P18 to the neu-
trophil-dominated airway secretions of CF patients.
To determine if toxicity differentials also exist between the
mature and proforms of D-P18, a hemolytic assay (4, 5, 22) was
performed with these peptides. While the active peptide induced
dose-dependent lysis of erythrocytes at concentrations between
50 and 500 M, its proform was almost devoid of an erythrolytic
effect (less than 3.5%) in this concentration range (Fig. 2).
Finally, 1H nuclear magnetic resonance (NMR) studies were
performed to assess if the activity differentials between D-P18
and Ac-E4-A3–D-P18 could be attributed to conformational
changes. In aqueous solutions, both peptides showed a lack of
secondary structure. In a 50% 2,2,2-trifluoroethanol (TFE-d3)–
water mixed solvent system, D-P18 was characterized by a left-
handed short -helical conformation between residues D-Ile8-
D-Leu14, while Ac-E4-A3–D-P18 adopted an extended
TABLE 1. Activities of peptides against representative pathogens associated with CFa
Peptide sequence Neutrophil elastaseconcn (g/ml)
MIC (M)
P. aeruginosa S. aureus
K-W-K-L-F-K-K-I-P-K-F-L-H-L-A-K-K-F-NH2 0 32 64
E-E-A-A-A-K-W-K-L-F-K-K-I-P-K-F-L-H-L-A-K-K-F-NH2 0 128 128
E-E-E-A-A-A-K-W-K-L-F-K-K-I-P-K-F-L-H-L-A-K-K-F-NH2 0 128 128
E-E-E-E-A-A-A-K-W-K-L-F-K-K-I-P-K-F-L-H-L-A-K-K-F-NH2 0 128 128
E-A-E-E-E-E-A-A-A-K-W-K-L-F-K-K-I-P-K-F-L-H-L-A-K-K-F-NH2 0 128 128
E-E-A-E-E-E-E-A-A-A-K-W-K-L-F-K-K-I-P-K-F-L-H-L-A-K-K-F-NH2 0 128 128
E-E-E-A-E-E-E-E-A-A-A-K-W-K-L-F-K-K-I-P-K-F-L-H-L-A-K-K-F-NH2 0 128 128
k-w-k-l-f-k-k-i-p-k-f-l-h-l-a-k-k-f-NH2 0 8 16
k-w-k-l-f-k-k-i-p-k-f-l-h-l-a-k-k-f-NH2 0.15 ND 16
Ac-E-E-E-E-A-A-A-k-w-k-l-f-k-k-i-p-k-f-l-h-l-a-k-k-f-NH2 0 128 128
Ac-E-E-E-E-A-A-A-k-w-k-l-f-k-k-i-p-k-f-l-h-l-a-k-k-f-NH2 0.075 128 32
Ac-E-E-E-E-A-A-A-k-w-k-l-f-k-k-i-p-k-f-l-h-l-a-k-k-f-NH2 0.15 16 16
Ac-E-E-E-E-A-A-A-OH  k-w-k-l-f-k-k-i-p-k-f-l-h-l-a-k-k-f-NH2 0 ND 16
A-A-k-w-k-l-f-k-k-i-p-k-f-l-h-l-a-k-k-f-NH2 0 ND 32
a Lowercase letters denote D-amino acids; uppercase letters denote L-amino acids. A, -alanine spacer; Ac, N-terminal acetylation. P. aeruginosa strain PAO1 and
S. aureus strain SH1000 were used. ND, not determined.
FIG. 1. Proposed approach for the generation of neutrophil elastase-dependent host defense peptide prodrugs and its application to Ac-E4-
A3–D-P18. Residue numbering used in the NMR studies is included as superscript numbers in the sequences of D-P18 and its propeptide; Ac
indicates N-terminal acetylation, OH is a C-terminal carboxyl group, and NH2 is a C-terminal amide group.
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-helical conformation between residues D-Lys8-D-Ile15 and
D-Lys17-D-Lys24 (Fig. 3). Therefore, the lower activities of the
propeptide most likely originate from the diminution of its net
charge and/or hydrophobicity (5, 12), rather than from a lower
capacity to adopt a functional conformation.
While NE preferentially cleaves peptides at residues with
medium-sized aliphatic side chains (e.g., valine) (2, 16), the
trialanine sequence was originally selected on the basis of
synthetic efficiencies, to facilitate the assembly of the tetraglu-
tamate sequence. Mass spectrometry analysis of samples from
reactivation assays with purified NE showed that this enzyme
hydrolyzes the linker between the first and second alanines
(Ala5-Ala6 bond) (Fig. 1), yielding a reactivated peptide with
two N-terminal alanines. A synthetic peptide with the corre-
sponding sequence had a MIC of 32 M against S. aureus.
Therefore, the control exerted on the activity of an HDP
through the conjugation of an oligo-glutamyl promoiety can be
further optimized by the sequence of the linker and its selec-
tion among the cleavage motifs of enzymes with narrow sub-
strate specificities, the sequence selected here being only suit-
able for topical application. This approach is currently being
developed to generate HDP prodrugs for targeted delivery.
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FIG. 3. Fingerprint region of the 200-ms two-dimensional nuclear
Overhauser effect spectra of propeptide Ac-E4-A3–D-P18 in a 50% TFE–
water mixed solvent system. The backbone assignment is indicated, along
with important short- and medium-range residue connectivities. A struc-
tural model of Ac-E4-A3–D-P18 is shown on the bottom left, with a ribbon
representation of the helical motif for the average conformation. The
N-terminal random coil segment is shown with a wire for clarity.
FIG. 2. Hemolytic activity of the active HDP D-P18 and its pro-
form, Ac-E4-A3–D-P18. The results are normalized to the 0.1% Triton
positive control. Statistics were carried out using a repeated-measures
analysis of variance followed by Dunnett’s post test. **, P  0.01.
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